ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.

doi:10.1038/tp.2012.115

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.

Translational psychiatry - 27 Nov 2012

Singh A B, Bousman C A, Ng C H, Byron K, Berk M

Abstract excerpt

The ATP-binding cassette family of transporter proteins, subfamily B (MDR/TAP), member 1 (ABCB1) (P-glycoprotein) transporter is a key component of the blood-brain barrier. Many antidepressants are subject to ABCB1 efflux. Functional polymorphisms of ABCB1 may influence central nervous system bioavailability of antidepressants subject to efflux. Single-nucleotide polymorphisms (SNPs) at rs1045642 (C3435T) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Citalopram

Share to Cyclohexanols

Share to Depressive Disorder, Major

Share to Psychiatric Status Rating Scales

Share to Selective Serotonin Reuptake Inhibitors

Share to Venlafaxine Hydrochloride

Source

Open in PubMed Open full text

Identifiers

PMID: 23188198
DOI: 10.1038/tp.2012.115
PMCID: PMC3565756

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.PMID 23188198Read ↗

Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.Semantic proximity Read ↗

ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.Semantic proximity Read ↗

ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.Semantic proximity Read ↗

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.Semantic proximity Read ↗

The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases.Semantic proximity Read ↗

ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis.Semantic proximity Read ↗

The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.Semantic proximity Read ↗

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic ReportSemantic proximity Read ↗

ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 Study.Semantic proximity Read ↗

ABCB1 genotyping in the treatment of depression.Semantic proximity Read ↗

ABCB1 C1236T, G2677TA and C3435T Genetic Polymorphisms and Antidepressant Response Phenotypes: Results from a Portuguese Major Depressive Disorder Cohort.Semantic proximity Read ↗

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.